TP53 and adenomyosis: Concerning the study endpoints, 37 (25.2%) patients showed the MMR-d signature (12 in the adenomyosis group and 25 in the no adenomyosis group), while 12 (8.2%) showed the p53-abn signature (3 in the adenomyosis group and 9 in the no adenomyosis group).